Skip to main content

Table 1 Associations between patient clinicopathologic factors and response to gefitinib

From: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Variable Total (n = 66) (%) Response to gefitinib treatment
PR (N = 25) SD (n = 20) PD (n = 21) P value (PR vs SD + DP) P value (PR + SD vs PD)
Sex       
 Male 37(56.1) 11 9 17 0.136 0.007
 Female 29(43.9) 14 11 4   
Age, yr       
 <67 34(51.5) 11 11 12 0.447 0.603
 ≥67 32(48.5) 14 9 9   
Smoking history       
 Never 22(33.3) 11 7 4 0.187 0.112
 Former 18(27.3) 6 5 7   
 Current 26(39.4) 8 8 10   
Histology       
 ADC 39(59.1) 20 12 7 0.022 0.004
 SCC 22(33.3) 4 6 12   
 ASC 5(7.6) 1 2 2   
Performance status       
 0-1 52(78.8) 19 16 17 0.760 0.421
 2-3 14(21.2) 6 4 6   
Disease stage       
 IIIB 10(15.2) 5 2 3 0.729 0.945
 IV 56(84.8) 22 16 18   
Prior chemotherapy       
 Yes 46(69.7) 18 16 12 0.790 0.157
 No 20(30.3) 7 4 9   
EGFR status       
 Wild-type 38(57.6) 9 11 18 0.018 0.005
 Mutation 22(33.3) 12 8 2   
 Unknown 6(9.1) 4 1 1   
MUC1 mRNA at B0       
 Median 5.95 4.87 5.18 8.76 0.116 0.005
 Range 1.16-17.56 1.16-8.75 2.45-10.73 2.24-17.56   
VEGF mRNA at B0       
 Median 4.88 4.21 4.72 7.65 0.122 0.004
 Range 1.07-15.32 1.07-9.86 1.62-10.24 2.31-15.32   
  1. PR, partial response; SD, stable disease; PD, progressive disease; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ASC, adenosquamous cell carcinoma.
\